Integra Lifesciences Holdings (IART) FCF Margin (2009 - 2026)
Integra Lifesciences Holdings (IART) reported FCF Margin of 1.29% for Q1 2026, up 921.0% on a YoY basis from 0.13% in Q1 2025, and down 3.72% sequentially from 1.24% in Q4 2025.
Integra Lifesciences Holdings (IART) FCF Margin (2009 - 2026) Analysis & Trends
Integra Lifesciences Holdings (IART) has 18 years of FCF Margin data on file, last reported at 1.29% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 921.0% year-over-year to 1.29%; the trailing twelve-month figure through Mar 2026 stood at 0.25% (up 120.0% YoY), and the FY2025 full-year result was 1.9%, down 345.0% from the prior year.
- FCF Margin slipped to 1.29% in Q1 2026, from 1.24% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 17.81% in Q4 2022 to a low of 10.5% in Q1 2025.
- A 5-year average of 4.22% and a median of 3.34% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin tumbled 1178 bps in 2023 and jumped 921 bps in 2026, its largest moves.
- Tracing IART's FCF Margin over 5 years: stood at 17.81% in 2022, then plunged by 52 bps to 8.62% in 2023, then plunged by 45 bps to 4.78% in 2024, then sank by 126 bps to 1.24% in 2025, then decreased by 4 bps to 1.29% in 2026.
- Business Quant data shows IART's FCF Margin at 1.29% in Q1 2026, 1.24% in Q4 2025, and 6.4% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Integra Lifesciences Holdings | 1.71 Bn | 1.45 Bn | 216.98 Mn | -1.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.29% |
| Dec 31, 2025 | -1.24% |
| Sep 30, 2025 | 6.40% |
| Jun 30, 2025 | -2.70% |
| Mar 31, 2025 | -10.50% |
| Dec 31, 2024 | 4.78% |
| Sep 30, 2024 | -1.88% |
| Jun 30, 2024 | 2.56% |
| Mar 31, 2024 | 0.08% |
| Dec 31, 2023 | 8.62% |
| Sep 30, 2023 | 3.58% |
| Jun 30, 2023 | 3.34% |
| Mar 31, 2023 | 3.27% |
| Dec 31, 2022 | 17.81% |
| Sep 30, 2022 | 15.36% |
| Jun 30, 2022 | 14.35% |
| Mar 31, 2022 | 9.30% |
| Dec 31, 2021 | 10.32% |
| Sep 30, 2021 | 19.51% |
| Jun 30, 2021 | 21.71% |